Shield Therapeutics (LON:STX) Hits New 12-Month High – Here’s Why

Shield Therapeutics plc (LON:STX)’s share price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as GBX 12.50 and last traded at GBX 12.20, with a volume of 1258025 shares traded. The stock had previously closed at GBX 12.15.

Wall Street Analyst Weigh In

Separately, Peel Hunt restated a “buy” rating and issued a GBX 15 price target on shares of Shield Therapeutics in a research note on Friday, November 7th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of GBX 15.

Shield Therapeutics Trading Up 0.4%

The firm has a market capitalization of £129.54 million, a PE ratio of -6.10 and a beta of 1.42. The firm has a 50 day simple moving average of GBX 9.71 and a 200 day simple moving average of GBX 7.42. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.